Trials / Completed
CompletedNCT04995042
A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR7280 | Drug: SHR7280 All participants receive SHR7280 alone. |
Timeline
- Start date
- 2021-09-24
- Primary completion
- 2023-05-24
- Completion
- 2023-05-25
- First posted
- 2021-08-06
- Last updated
- 2023-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04995042. Inclusion in this directory is not an endorsement.